These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 23643932

  • 1. Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.
    Hanson J, Ferreirós N, Pirotte B, Geisslinger G, Offermanns S.
    Biochem Pharmacol; 2013 Jun 15; 85(12):1795-802. PubMed ID: 23643932
    [Abstract] [Full Text] [Related]

  • 2. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.
    Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, Godson C.
    FASEB J; 2010 Nov 15; 24(11):4240-9. PubMed ID: 20570963
    [Abstract] [Full Text] [Related]

  • 3. Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function.
    Planagumà A, Domenech T, Jover I, Ramos I, Sentellas S, Malhotra R, Miralpeix M.
    Clin Exp Immunol; 2013 Aug 15; 173(2):298-309. PubMed ID: 23607720
    [Abstract] [Full Text] [Related]

  • 4. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.
    Ge Y, Zhang S, Wang J, Xia F, Wan JB, Lu J, Ye RD.
    FASEB J; 2020 May 15; 34(5):6920-6933. PubMed ID: 32239559
    [Abstract] [Full Text] [Related]

  • 5. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity.
    Simiele F, Recchiuti A, Mattoscio D, De Luca A, Cianci E, Franchi S, Gatta V, Parolari A, Werba JP, Camera M, Favaloro B, Romano M.
    FASEB J; 2012 Mar 15; 26(3):1323-33. PubMed ID: 22131270
    [Abstract] [Full Text] [Related]

  • 6. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.
    Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C.
    Pharmacol Rev; 2006 Sep 15; 58(3):463-87. PubMed ID: 16968948
    [Abstract] [Full Text] [Related]

  • 7. Epigenetic regulation of the formyl peptide receptor 2 gene.
    Simiele F, Recchiuti A, Patruno S, Plebani R, Pierdomenico AM, Codagnone M, Romano M.
    Biochim Biophys Acta; 2016 Oct 15; 1859(10):1252-8. PubMed ID: 27424221
    [Abstract] [Full Text] [Related]

  • 8. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.
    Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, Perretti M.
    J Immunol; 2011 Apr 15; 186(8):4905-14. PubMed ID: 21398608
    [Abstract] [Full Text] [Related]

  • 9. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors.
    Forsman H, Dahlgren C.
    Scand J Immunol; 2009 Oct 15; 70(4):396-402. PubMed ID: 19751275
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
    Gabl M, Holdfeldt A, Sundqvist M, Lomei J, Dahlgren C, Forsman H.
    Biochem Pharmacol; 2017 Dec 01; 145():114-122. PubMed ID: 28855087
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium.
    Chinthamani S, Odusanwo O, Mondal N, Nelson J, Neelamegham S, Baker OJ.
    Am J Physiol Cell Physiol; 2012 Apr 01; 302(7):C968-78. PubMed ID: 22205391
    [Abstract] [Full Text] [Related]

  • 14. What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4?
    Forsman H, Önnheim K, Andreasson E, Dahlgren C.
    Scand J Immunol; 2011 Sep 01; 74(3):227-234. PubMed ID: 21535079
    [Abstract] [Full Text] [Related]

  • 15. Lipoxin A₄-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair.
    Buchanan PJ, McNally P, Harvey BJ, Urbach V.
    Am J Physiol Lung Cell Mol Physiol; 2013 Jul 15; 305(2):L193-201. PubMed ID: 23686859
    [Abstract] [Full Text] [Related]

  • 16. Lipoxin A4 Attenuates the Inflammatory Response in Stem Cells of the Apical Papilla via ALX/FPR2.
    Gaudin A, Tolar M, Peters OA.
    Sci Rep; 2018 Jun 11; 8(1):8921. PubMed ID: 29892010
    [Abstract] [Full Text] [Related]

  • 17. Glucocorticoids co-interact with lipoxin A4 via lipoxin A4 receptor (ALX) up-regulation.
    Hashimoto A, Murakami Y, Kitasato H, Hayashi I, Endo H.
    Biomed Pharmacother; 2007 Jan 11; 61(1):81-5. PubMed ID: 17184966
    [Abstract] [Full Text] [Related]

  • 18. Lipoxin A₄ modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism.
    Ramon S, Bancos S, Serhan CN, Phipps RP.
    Eur J Immunol; 2014 Feb 11; 44(2):357-69. PubMed ID: 24166736
    [Abstract] [Full Text] [Related]

  • 19. Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.
    Lee HJ, Park MK, Lee EJ, Lee CH.
    Int J Biochem Cell Biol; 2013 Dec 11; 45(12):2801-7. PubMed ID: 24120851
    [Abstract] [Full Text] [Related]

  • 20. N-formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX receptor with regard to the major processes governing chemoattractant receptor regulation, expression at the cell surface, and phosphorylation.
    Rabiet MJ, Macari L, Dahlgren C, Boulay F.
    J Biol Chem; 2011 Jul 29; 286(30):26718-31. PubMed ID: 21543323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.